JP2004500325A - 細胞増殖障害を処置するための組成物および方法 - Google Patents

細胞増殖障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP2004500325A
JP2004500325A JP2000617923A JP2000617923A JP2004500325A JP 2004500325 A JP2004500325 A JP 2004500325A JP 2000617923 A JP2000617923 A JP 2000617923A JP 2000617923 A JP2000617923 A JP 2000617923A JP 2004500325 A JP2004500325 A JP 2004500325A
Authority
JP
Japan
Prior art keywords
cells
antagonist
tumor
human
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000617923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500325A5 (enExample
Inventor
フリドマン，　エルベ
タルトゥール，　エリック
バンシュ，　ジャック
フォシェ，　フランソワ
レベッキュ，　セルジュ　ジ．　ウー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Curie
Merck Sharp and Dohme LLC
Original Assignee
Institut Curie
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie, Schering Corp filed Critical Institut Curie
Publication of JP2004500325A publication Critical patent/JP2004500325A/ja
Publication of JP2004500325A5 publication Critical patent/JP2004500325A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000617923A 1999-05-17 2000-03-27 細胞増殖障害を処置するための組成物および方法 Pending JP2004500325A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401191A EP1053751A1 (en) 1999-05-17 1999-05-17 Compositions and methods for treating cell proliferation disorders
PCT/US2000/008081 WO2000069463A1 (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Publications (2)

Publication Number Publication Date
JP2004500325A true JP2004500325A (ja) 2004-01-08
JP2004500325A5 JP2004500325A5 (enExample) 2007-05-24

Family

ID=8241974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000617923A Pending JP2004500325A (ja) 1999-05-17 2000-03-27 細胞増殖障害を処置するための組成物および方法

Country Status (6)

Country Link
EP (2) EP1053751A1 (enExample)
JP (1) JP2004500325A (enExample)
AU (1) AU4033900A (enExample)
CA (1) CA2373938A1 (enExample)
MX (1) MXPA01011923A (enExample)
WO (1) WO2000069463A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP5068270B2 (ja) * 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2569335B1 (en) * 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
CN103384682B (zh) 2011-01-14 2017-04-12 Ucb医药有限公司 结合il‑17a和il‑17f的抗体分子
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591529A3 (en) * 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
AU9482498A (en) * 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
DE29820466U1 (de) * 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010024042, ＷＡＫＡＳＵＧＩ， Ｓ ｅｔ ａｌ, Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 1998, Ｖｏｌ．３９, ｐ．６ *
JPN6010024044, ＴＡＲＴＯＵＲ， Ｅ ｅｔ ａｌ, Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 1998, Ｖｏｌ．３９, ｐ．６５３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体
US8119131B2 (en) 2004-08-05 2012-02-21 Novartis Ag IL-17 antagonistic antibodies
US8617552B2 (en) 2004-08-05 2013-12-31 Novarts Ag IL-17 antibodies
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法

Also Published As

Publication number Publication date
WO2000069463A1 (en) 2000-11-23
EP1251872A1 (en) 2002-10-30
MXPA01011923A (es) 2003-10-15
AU4033900A (en) 2000-12-05
EP1053751A1 (en) 2000-11-22
CA2373938A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
Klein et al. Survival and proliferation factors of normal and malignant plasma cells
JP2004500325A (ja) 細胞増殖障害を処置するための組成物および方法
Urashima et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
JP3040121B2 (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US8097250B2 (en) Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP3825255B2 (ja) 炎症媒介物質のアンタゴニスト
US20090142806A1 (en) Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
AU2004289098B2 (en) Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease
KR20170121199A (ko) 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
CA2358693A1 (en) Anti-ccr4 antibodies and methods of use therefor
HU221343B1 (en) Use of anti-vegf antibodies for the treatment of cancer
JP2009155335A (ja) 抗癌療法のためのマクロファージマイグレーション阻害因子アンタゴニストの使用
US20130302277A1 (en) Method of treatment
CN104870013A (zh) 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
EP1022027A1 (en) Tumor necrosis factor antagonists and their use in endometriosis
CN116348488A (zh) 犬白介素-31受体α的犬源化大鼠抗体
WO2000044407A1 (en) Materials and methods to inhibit hodgkin and reed sternberg cell growth
KR20220042067A (ko) Gm-csf 길항제를 사용한 암의 치료
JPH03232485A (ja) ハイブリドーマ細胞株の製造方法
EP1283217A2 (en) Antibodies against the IL-8 receptor, and their therapeutic uses
US7892767B2 (en) Phosphospecific chemokine receptor antibodies
US20020068060A1 (en) Cytokine antagonists
JP2024545101A (ja) 抗ｃｌｅｖｅｒ－１がん治療を誘導するための炎症マーカーの使用方法
HK1119389A (en) Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101014